Publications by authors named "F Quilot"
Introduction: The emergence of diverse resistance mechanisms after osimertinib therapy, including on-target epidermal growth factor receptor (EGFR) mutations and off-target alterations, warrants investigation of novel therapeutics to overcome these challenges and improve patient outcomes.
Methods: COMPOSIT was a French, retrospective, multicenter, cohort study of the effectiveness and tolerability of osimertinib in combination with other targeted therapies in patients with advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC) who harbored other oncogenic drivers as primary or acquired resistance mechanisms. Real-world progression-free survival (rwPFS), overall survival (OS), and objective response rate (ORR) were the primary endpoints.
Article Synopsis
- Small cell lung cancer (SCLC) is a highly aggressive cancer leading to significant mortality, with standard treatment for decades being platinum-etoposide-based chemotherapy, resulting in a median survival of just 10 months.
- Recent research has shown that adding immunotherapy to chemotherapy improves overall survival in extensive-stage SCLC, leading to its adoption as the standard first-line treatment since 2019.
- A study involving 118 patients found that while the combination of immunotherapy and chemotherapy did not significantly improve progression-free survival compared to chemotherapy alone, it did result in improved overall survival, especially for those receiving additional palliative thoracic radiotherapy.